| P50 | author | Tiziana Pressiani | Q91670431 |
| | Nicola Personeni | Q38524333 |
| | Lorenza Rimassa | Q38524354 |
| P2093 | author name string | Tiziana Pressiani | |
| | Nicola Personeni | |
| | Lorenza Rimassa | |
| P2860 | cites work | Sorafenib in advanced hepatocellular carcinoma | Q27861075 |
| | New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) | Q28131668 |
| | Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial | Q29547903 |
| | Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial | Q33410643 |
| | Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial | Q33423800 |
| | PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation | Q33569771 |
| | Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage | Q34144848 |
| | Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial | Q34663499 |
| | SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma. | Q50454368 |
| | ADI-PEG 20 Plus Best Supportive Care versus Placebo Plus Best Supportive Care in Patients with Advanced Hepatocellular Carcinoma. | Q52586036 |
| | SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma. | Q52677129 |
| | Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial | Q56355520 |
| | Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma | Q56373211 |
| | Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study | Q56384328 |
| | Hepatocellular carcinoma | Q58020832 |
| | Hepatocellular Carcinoma: A Global Disease in Need of Individualized Treatment Strategies | Q61054495 |
| | Lenvatinib May Drastically Change the Treatment Landscape of Hepatocellular Carcinoma | Q88379404 |
| | Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial | Q89012806 |
| | Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial | Q91147767 |
| | Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial | Q34786090 |
| | CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice | Q35528287 |
| | Intratumoral myeloid cells regulate responsiveness and resistance to antiangiogenic therapy. | Q35627827 |
| | Modified RECIST (mRECIST) assessment for hepatocellular carcinoma | Q37696396 |
| | Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma | Q37710134 |
| | Modulation of immunity by antiangiogenic molecules in cancer | Q38074154 |
| | Dose Finding of Lenvatinib in Subjects With Advanced Hepatocellular Carcinoma Based on Population Pharmacokinetic and Exposure-Response Analyses | Q38754388 |
| | Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial | Q38785510 |
| | Hepatocellular carcinoma: Exploring the impact of ethnicity on molecular biology. | Q38884212 |
| | Simultaneous blockade of programmed death 1 and vascular endothelial growth factor receptor 2 (VEGFR2) induces synergistic anti-tumour effect in vivo | Q39163764 |
| | VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer | Q39252038 |
| | A vascular endothelial growth factor receptor-2 inhibitor enhances antitumor immunity through an immune-based mechanism | Q40112546 |
| | Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial | Q40231174 |
| | Safety and Pharmacokinetics of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma | Q41187204 |
| | Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study | Q43691230 |
| | Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. | Q45980006 |
| | Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial | Q47376936 |
| | Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial | Q50046367 |
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | hepatocellular carcinoma | Q1148337 |
| | immunotherapy | Q1427096 |
| | lenvatinib | Q6523413 |
| P304 | page(s) | 31-39 | |
| P577 | publication date | 2019-01-31 | |
| P1433 | published in | Journal of hepatocellular carcinoma | Q27727369 |
| P1476 | title | Lenvatinib for the treatment of unresectable hepatocellular carcinoma: evidence to date | |
| P478 | volume | 6 | |